# Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

> **NCT01281852** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Recurrent Cervical Carcinoma
- Stage IVB Cervical Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Cisplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01281852
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-14
- **Primary completion:** 2017-02-11
- **Final completion:** 2017-02-11
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01281852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01281852, "Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01281852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*